- Home
- SKK vs NERV Comparison
SKK vs NERV Comparison
Compare SKK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- NERV
- Stock Information
- Founded
- SKK 2013
- NERV 2007
- Country
- SKK Singapore
- NERV United States
- Employees
- SKK N/A
- NERV N/A
- Industry
- SKK
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SKK
- NERV Health Care
- Exchange
- SKK NYSE
- NERV Nasdaq
- Market Cap
- SKK 12.5M
- NERV 10.7M
- IPO Year
- SKK 2024
- NERV 2014
- Fundamental
- Price
- SKK $0.83
- NERV $1.62
- Analyst Decision
- SKK
- NERV Hold
- Analyst Count
- SKK 0
- NERV 1
- Target Price
- SKK N/A
- NERV $5.00
- AVG Volume (30 Days)
- SKK 198.1K
- NERV 31.3K
- Earning Date
- SKK 02-14-2025
- NERV 04-30-2025
- Dividend Yield
- SKK N/A
- NERV N/A
- EPS Growth
- SKK N/A
- NERV N/A
- EPS
- SKK N/A
- NERV 0.19
- Revenue
- SKK $8,631,000.00
- NERV N/A
- Revenue This Year
- SKK N/A
- NERV N/A
- Revenue Next Year
- SKK N/A
- NERV N/A
- P/E Ratio
- SKK N/A
- NERV $8.84
- Revenue Growth
- SKK N/A
- NERV N/A
- 52 Week Low
- SKK $0.61
- NERV $1.42
- 52 Week High
- SKK $11.45
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- NERV 38.16
- Support Level
- SKK N/A
- NERV $1.53
- Resistance Level
- SKK N/A
- NERV $1.74
- Average True Range (ATR)
- SKK 0.00
- NERV 0.16
- MACD
- SKK 0.00
- NERV 0.01
- Stochastic Oscillator
- SKK 0.00
- NERV 36.43
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are primarily the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.